Building knowledge around diagnosis, treatment and care pathways can reduce compound attritions.
Sensyne’s Biomarker Search service will, where possible, link genomic or panomic data to real world Electronic Patient Record (EPR) data to allow the association between SNPs, protein and disease expression to further increase confidence in target selection and facilitate the development of personalised medicines.
There is increasing appetite globally for outcomes-based or value-based pricing agreements. Tracking these real world outcomes however can be complex and resource intensive.
Sensyne Health can act as a trusted intermediary in the provision of data between supplier and payer using real world data obtained from the SENSIGHT platform.
Through the integration of large, analysed patient imaging cohorts into the SENSIGHT platform, users will be able to interrogate specific disease progression and outcomes using chest CT, MRI, RECIST and other markers.
SENSIGHT’s development and testing services allow clinical developers to develop, test and train new algorithms on single or multiple data sets.
Leveraging large anonymised patient data sets and clinical expertise within the SENSIGHT platform, along with Sensyne’s imaging expertise, enables the rapid development of prototype AI applications to address research problems.